ARTICLE | Clinical News

Rilotumumab: Phase II data

May 30, 2011 7:00 AM UTC

Data from 142 evaluable patients with wild-type K-Ras mCRC in the double-blind Phase II portion of a Phase Ib/II trial showed Vectibix panitumumab plus AMG 102 (n=48) led to 15 partial responses (PRs) and 19 cases of stable disease (SD) compared to 10 PRs and 17 cases of SD for Vectibix plus placebo (n=48). Additionally, Vectibix plus AMG 479 produced 10 PRs and 18 cases of SD (n=46). Median PFS for the AMG 102, placebo and AMG 479 treatment groups was 5.2, 3.7 and 5.3 months, respectively. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...